No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
LUCD Lucid Diagnostics
- 0.683
- +0.013+1.94%
Close Apr 26 16:00 ET
- 0.690
- +0.007+1.00%
Post 18:24 ET
33.74MMarket Cap-542P/E (TTM)
0.700High0.664Low123.81KVolume0.678Open0.670Pre Close84.16KTurnover0.76%Turnover RatioLossP/E (Static)49.39MShares1.85052wk High-1.61P/B11.08MFloat Cap0.63052wk Low--Dividend TTM16.22MShs Float13.520Historical High--Div YieldTTM5.36%Amplitude0.630Historical Low0.679Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Lucid Diagnostics: Strong Buy Rating With Significant Market Potential Despite Near-Term Losses
Express News | Lucid Diagnostics Inc : Ascendiant Capital Markets Cuts Target Price to $8 From $8.5
Buy Rating Affirmed for Lucid Diagnostics Amidst Strong EsoGuard Testing Growth and Clear Reimbursement Path
Analysts Are Bullish on Top Healthcare Stocks: Lucid Diagnostics (LUCD), Werewolf Therapeutics (HOWL)
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...
Buy Rating Affirmed for PAVmed With Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price Target
Comments
Eh!
$Lucid Diagnostics(LUCD.US$ Lucid Diagnostics posted Q4 revenues of $1 million, marking a 33% increase from Q3 and a 829% increase annually.
Non-GAAP net loss for the quarter was $9.9 million, showing a slight increase from Q3 but a year-over-year decrease of $700,000.
The company had a year-end cash balance of $18.9 million, supported by a recent financing of $18.1 million.
Approximately 50% of the claims submitted have been adjudicated, with an averaging payment of $1,800.
The projected re...
Non-GAAP net loss for the quarter was $9.9 million, showing a slight increase from Q3 but a year-over-year decrease of $700,000.
The company had a year-end cash balance of $18.9 million, supported by a recent financing of $18.1 million.
Approximately 50% of the claims submitted have been adjudicated, with an averaging payment of $1,800.
The projected re...
1
$Lucid Diagnostics(LUCD.US$ Lucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
PR Newswire· 1 min ago
The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participants at almost 2.5K per billable test
PR Newswire· 1 min ago
The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participants at almost 2.5K per billable test
Watching for pre R/S pop
$Lucid Diagnostics(LUCD.US$ Lucid Diagnostics: 1-for-15 Reverse Stk Split to Be Effective as of Market Open on Dec 7 >LUCD
Dow Jones· 1 min ago
Dow Jones· 1 min ago
$Lucid Diagnostics(LUCD.US$ based off analysts rating, I will hold for the walk back up
ColumnsTop upgrades and downgrades on 12/27
Monday, December 27, 2021
By Danilo
$InnovAge Holding(INNV.US$$Lucid Diagnostics(LUCD.US$$Innovid(CTV.US$$Chesapeake Energy(CHK.US$
By Danilo
$InnovAge Holding(INNV.US$$Lucid Diagnostics(LUCD.US$$Innovid(CTV.US$$Chesapeake Energy(CHK.US$
37
5
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg